Waverley Pharma Inc's stock remains stable despite limited market activity and recent financial performance updates.
Waverley Pharma Inc (WAVE.V) has seen no significant changes in its stock price this week, closing at C$0.01 on Wednesday. The company continues to navigate its operational challenges while reporting notable revenue growth in its recent financial filings.
Waverley Pharma Inc
WAVE.V
WAVE.V
Waverley Pharma Inc
WealthAwesomeMarket cap
$540,000
52W high
$0.03
52W low
$0.01
1W change
+100.00%
Beta
1.46
Analyst Price Targets
Based on analyst covering WAVE · as of Sep 17, 2026
Wall Street analysts forecast WAVE stock price to rise 49900.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$10.00
+49900.0% Upside
Current Price
C$0.02
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on WAVE's historical volatility
30-Day Vol
518.1%
Annualized
90-Day Vol
520.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.02
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.02 | C$0.00 – C$0.13 |
| 60 trading days | C$0.02 | C$0.00 – C$0.28 |
| 90 trading days | C$0.02 | C$0.00 – C$0.53 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: With a market cap of only C$810,000, Waverley Pharma's stock is trading at the lower end of its 52-week range. Investors should consider the company's financial trajectory and operational developments as they assess future potential.
Waverley Pharma Reports 183.9% Revenue Growth in 2025
The company's reported revenue of CAD 1.35 million for the fiscal year 2025 reflects a strong increase, but the net loss of CAD 0.499 million highlights ongoing financial challenges.
Bull case
Waverley Pharma reported impressive revenue growth of 183.9% for the fiscal year ending December 31, 2025. This suggests a positive trend in its business operations and potential for future success.
Bear case
Despite the revenue growth, Waverley Pharma is still facing significant losses and has a negative profit margin. This raises concerns about the company's long-term sustainability and ability to turn a profit.
Price Action Overview
Waverley Pharma Inc's stock has shown little movement recently, closing at C$0.01 on Wednesday. Over the past week, the stock has remained unchanged, reflecting a year-to-date decline of 40%. The latest trading volume was 5,000 shares, significantly below the 20-day average volume of 14,137 shares.
Company News and Developments
There have been no major announcements or news releases from Waverley Pharma this week. However, recent reports highlighted the company's financial performance for 2025, where it achieved a revenue of CAD 1.35 million, up 183.9% from the previous year. The narrowing net loss from CAD 0.947 million in 2024 to CAD 0.499 million indicates some financial improvement, albeit still in the negative.
Technical Picture
Waverley Pharma's stock is trading at the lower end of its 52-week range of C$0.01 to C$0.03, currently at 25% of this range. The stock is below both its 50-day and 200-day moving averages, which stand at C$0.02, indicating a bearish trend in the short to medium term. The stock has a beta of 1.22, suggesting higher volatility compared to the broader market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
